Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SKIKON.CO
- Price
- 825.90
- Stock movement down
- -9.50 (-1.09%)
- Company name
- SKAGEN Kon-Tiki A
- Exchange
- (CO ,
- Currency
- DKK )
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 19.58%
- 3 year return
- -1.52%
- 5 year return
- 9.62%
- 10 year return
- 3.84%
Last updated: 2025-09-05
DIVIDENDS
SKIKON.CO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 862.50 |
| Daily high | 862.50 |
| Daily low | 862.50 |
| Daily Volume | 0K |
| All-time high | 1070.92 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SKIKON.CO | S&P500 | |
| Current price drop from All-time high | -19.46% | -1.06% |
| Highest price drop | -57.82% | -56.47% |
| Date of highest drop | 27 Oct 2008 | 9 Mar 2009 |
| Avg drop from high | -14.05% | -10.99% |
| Avg time to new high | 26 days | 12 days |
| Max time to new high | 654 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
SKAGEN - Kon-Tiki fund is an open-ended equity mutual fund launched and managed by Skagen AS. The fund invests in public equity markets of emerging countries across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund invests in stocks of companies across diversified market capitalizations. It invests in value stocks of companies. It benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. SKAGEN - Kon-Tiki fund was formed on April 5, 2002 and is domiciled in Norway.
Employees
0
Investor relations
-
SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Lysaker, 28 October 2025 The suspension is lifted for the below funds, and the live trading on Nasdaq Copenhagen can resume. Regards Storebrand Asset Management AS Contacts: Henrik Budde Gantzel, Dire...
October 28, 2025
Lysaker, 28 October 2025 The below funds are suspended from the live trading on Nasdaq Copenhagen due to technical issues which affect NAV calculations, and hence, challenges to provide intrinsic valu...
October 28, 2025
Lysaker, 27 October 2025 This is a re-submission of the announcement posted at 14:46, with reference to the correct fund (SKAGEN Focus A) at the bottom of this text. With reference to Nasdaq Copenhage...
October 27, 2025
Lysaker, 27 October 2025 With reference to Nasdaq Copenhagen's rules for issuers of UCITS units, we hereby notify that incorrect intrinsic values were reported on 24 October for SKAGEN Focus A as deta...
October 27, 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
September 9, 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
September 9, 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
September 9, 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
September 9, 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
September 9, 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
September 9, 2025
Next page